Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Upcoming Meetings: Clinical Laboratory Improvement Advisory Committee

This article was originally published in The Gray Sheet

Executive Summary

Clinical Laboratory Improvement Advisory Committee: Scheduled to meet March 5-6 at the Centers for Disease Control and Prevention in Atlanta, according to a Feb. 14 Federal Register notice. The agenda for March 5 entails an orientation for new CLIAC members. On March 6, CDC will provide an update on the status of proposed rules for cytology, Accurate and Precise Technology, and waiver criteria, while the Health Care Financing Administration will provide an update on implementation of the Clinical Laboratory Improvement Amendments and FDA will offer a general update. Also slated are "presentations on the use of automated cytology instruments" and demonstrations of "computer-based cytology proficiency testing (PT) developed in cooperative agreement with CDC." For more information, contact CDC's John Ridderhof at 770/488-7660...

You may also be interested in...



Finland's Forendo Attracts Big Pharma For Liver Disease R&D

Turku, Finland-based Forendo Pharma has entered into a license and collaboration deal with Novartis involving the identification of novel drugs to treat chronic liver diseases.


 

Decision Time For MSD/AZ, Lilly, Kite EU Fast-Track Hopes

Three accelerated assessment requests will either be granted or rejected this week at the European Medicines Agency.

Singapore And Malaysia Test Joint Evaluation Of Generics

A new work sharing pilot has been launched to evaluate jointly generic drugs intended for launch in Singapore and Malaysia.

UsernamePublicRestriction

Register

MT005511

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel